DOAC-Stop in lupus anticoagulant testing: Direct oral anticoagulant interference removed in most samples.

ABSTRACT:

Background

The use of direct oral anticoagulants (DOACs) is a convenient therapeutic option for patients at risk of thrombosis. DOACs interfere with clot-based testing for the identification of lupus anticoagulant antibodies (LACs) in patients with antiphospholipid syndrome (APS), a common cause of acquired thrombotic disease.

Objectives

To evaluate a commercially available reagent DOAC-Stop for the removal of DOAC interference encountered in LAC testing.

Patients/methods

We collected a cohort of 73 test samples from patients on DOAC therapy identified at a large institutional coagulation laboratory from March to December 2019, along with samples from 40 LAC positive and negative control patients not on therapy. Samples were treated with DOAC-Stop and tested for anti-

SUBMITTER: Baker SA 

PROVIDER: S-EPMC7938630 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature